Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

at or before the EASL meeting

and/or the Digestive Disease Week meeting. These meetings will take

place in April and May, respectively.

-- The company expects to initiate its 14-day triple combination study of

ITMN-191 in combination with Pegasys(R) and ribavirin, in the second

quarter of 2008. The study design and timeline will be shared at study

initiation.

-- An Investigational New Drug (IND) application is expected to be filed

by Roche for ITMN-191/R7227 in the second half of 2008 to gain FDA

approval to study the compound in the United States.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EST to discuss its financial results for the fourth quarter and full year 2007, its forward-looking financial guidance and its clinical development programs. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 32601453. A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 32601453. The webcast will remain available on the company's website until the next earnings call.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (I
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... ... joint disease. , Equine cervical facet joint problems can be caused by ... and can cause impingement of nerve roots or of the spinal cord itself. ...
(Date:9/1/2015)... ... 2015 , ... Leading CEOs, CSOs, CMOs, and heads of ... prominent academics and key investors for Neuro Advance Boston, October 14, 2015 at ... , Neuro Advance Boston focuses on the latest developments and opportunities in neuroscience ...
(Date:9/1/2015)... Sept. 1, 2015   Medfusion, Inc., ... relationship between doctors and patients, today announced a ... N.C. -based venture capital firms.   ... association with Bull City Venture Partners and Hatteras ... Founder and Executive Chairman. "Both firms, experience working ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new host-based ... researchers at the Keck Graduate Institute and its collaborators. The discovery has the ... were published online on August 27 by Scientific Reports, an open access research ...
Breaking Biology Technology:VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4
...   Synthetic Biologics, Inc. (NYSE Amex: SYN ), ... medicines for serious illnesses, announced today that to improve ... split the roles of Chairman and Chief Executive Officer, ... independent, non-executive Chairman of the Board. Mr. Kraws has ...
... 10, 2012   GeneLink, Inc. (OTC Bulletin ... biotech company, reports financial results for the fiscal year ended ... , The Company reached an agreement in October 2011 ... to Capsalus Corp (OTCBB:WELL.OB, or "Capsalus"). Capsalus assumed management of ...
... Laboratory has entered into a contractual agreement for ancillary ... Network and their 8.6 million lives network. ... pioneer of claims optimization, Stratose (formerly operating as Coalition ... KeyClaims) works to reduce the cost and ensure the ...
Cached Biology Technology:Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman 2Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman 3GeneLink Reports 2011 Financial Results 2GeneLink Reports 2011 Financial Results 3Aviir Laboratories Announce National Agreement with Stratose 2Aviir Laboratories Announce National Agreement with Stratose 3
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Saudi Arabia Biomedical Sensors Market - Growth, ... The Saudi Arabia Biomedical Sensors market ... CAGR of 3.64% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
(Date:8/24/2015)... Aug. 24, 2015  Based on its recent analysis of ... the 2015 African Biometrics Company of the Year Award. DERMALOG ... commercial success in Africa . It has ... it has implemented one of the largest biometric mass applications ... as the Central Bank of Nigeria ...
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... Duke University Medical Center and Laboratory Corporation of ... formation of a joint venture to commercialize new ... the translation of newly discovered biomarkers into widely ... responses, predict disease progression, and evaluate any number ...
... NASA,s Aqua and Terra satellites fly around the ... land changes. Over the last three days these satellites ... plume from the Eyjafjallajkull volcano in Iceland. Eyjafjallajkull ... spewing ash into the atmosphere. Volcanic eruptions are important ...
... 2010 Scientists from The Scripps Research Institute have provided ... mutations lead to Type 1 diabetes. This new molecular understanding ... other autoimmune diseases. The study was published in an ... on April 19, 2010, and will appear in the ...
Cached Biology News:Duke, LabCorp combine forces to create the Biomarker Factory 22 NASA Satellites Capture Last 3 Days of Eyjafjallajokull's Ash Plume 2Scripps Research scientists reveal how genetic mutations may cause type 1 diabetes 2Scripps Research scientists reveal how genetic mutations may cause type 1 diabetes 3
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
... 20 Plasma Immunodepletion Kit specifically removes 20 ... plasma or serum in preparation for further ... into the plasma proteome whether you use ... chromatography or go straight to mass spectrometry. ...
... a direct antibiotic-based selection ... Recombinant selection depends solely ... the need for costly ... and inexpensive process provides ...
Biology Products: